Class: Platelet Aggregation Inhibitor
Dosage Forms. Tablet: 25 mg, 50 mg, 75 mg
Common FDA Label Indication and Dosing.
1. Thromboprophylaxis after heart valve replacement: 75-100 mg po qid as an adjunct to warfarin therapy
Off-Label Uses. None
MOA. Inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes resulting in an increase in local concentrations of adenosine, which is a coronary vasodilator and a platelet aggregation inhibitor.
Drug Characteristics: Dipyridamole
Medication Safety Issues: Dipyridamole
Drug Interactions: Dipyridamole
Adverse Reactions: Dipyridamole
Efficacy Monitoring Parameters. Prevention of AMI, stroke, other thrombotic complications.
Toxicity Monitoring Parameters. Signs/symptoms of dizziness, GI distress.
Key Patient Counseling Points. Rise slowly from a sitting/supine position. Avoid alcohol.
Clinical Pearls. Safety and effectiveness in pediatric patients have not been studied. Injectable product also available for radionuclide cardiac perfusion studies. Oral combination product with dipyridamole and aspirin also available. Use with caution in the elderly.